[1] 王腊梅,孔祥阳,王昆华.肠道菌群与艾滋病关系的研究进展[J].细胞与分子免疫学杂志,2016,32(6):859-862. [2] 范铮,喻剑华.艾滋病与肠道菌群研究进展[J].实用医学杂志,2020,36(9 ):1148-1151. [3] 中华医学会感染病学分会艾滋病学组中国疾病预防控制中心.艾滋病诊疗指南(2018版)[J/CD].新发传染病电子杂志,2019,4(2):65-84. [4] CECCARELLIA G, STATZUB M, SANTINELLIB L, et al.Challenges in the management of HIV infection: update on the role of probiotic supplementation as a possible complementary therapeutic strategy for cART treated people living with HIV/AIDS[J]. Exp.Opin Biol Ther, 2019, 19(9):949-965. [5] ZEVIN AS,MCKINNON L,BERGENER A,et al.Review Microbial translocation and microbiome dysbiosis in HIV-associated immune activation[J]. Curr Opin HIV AIDS,2016,11(2): 182-190. [6] 姜达琳,刘国旺.艾滋病与肠道菌群的研究进展[J]. 继续医学教育,2020,34(5):129-131. [7] NOWAK P, TROSEID M, AVERSHINA E, et al.Gutmicrobiotadiversity predict immune status in HIV-1infection[J].AIDS,2015,29(18):2409-2418. [8] 王思苑,孙丽琴,段司沁,等.CD4/CD8比值在HIV感染者中临床分析及其预测价值[J/CD].新发传染病电子杂志, 2019,4(2):91-96 [9] 刘文静,孙宏莉,张小江,等.2014~2018年北京协和医院酵母菌血流感染菌种分布和抗真菌药物敏感性分析[J].中国真菌学杂志,2019,14(6):357-361. [10] WALKER L, SOOD PD, LENARDON M et al.The Viscoelastic Properties of the Fungal Cell Wall ALLOW Traffic of AmBisome as Intact Liposome Vesicles[J].mBio,2018,9(1):e02383-17. [11] 沈银忠. 两性霉素B脂质体的临床合理应用[J].中国抗生素杂志,2015,40(7):495-499. [12] VERMES A, GUCHELAR HJ, DANKERT J.Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions[J]. J Antimicrob Chemother, 2000, 46(2):171-179. [13] 宋树林,卢亦波,彭认平,等.艾滋病合并淋巴结核病患者疗效观察[J/CD].新发传染病电子杂志,2020,(4)5:253-257. [14] 龙海燕,冯萍.抗生素相关性腹泻患者艰难梭菌和白念珠菌检测与临床特征分析[J].华西医学,2018,33(5):71-76. [15] KIM CJ, WALMSLEY SL, RABOUDA JM, et al.Can probiotics reduce inflammation and enhance gut immune health in people living with HIV: study designs for the probiotic visbiome for inflammation and translocation (PROOV IT) pilot trials[J]. HIV Clin Trials,2016,17(4):147-157. [16] 余邹邹,李云,宋银宏.人类免疫缺陷病毒感染与肠道菌群的变化研究进展[J]. 病毒学报,2018,34(4):142-149. |